Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$23.46 - $45.07 $17,172 - $32,991
732 Added 2.03%
36,760 $1.21 Million
Q4 2023

Feb 13, 2024

BUY
$17.69 - $30.76 $21,546 - $37,465
1,218 Added 3.5%
36,028 $980,000
Q3 2023

Nov 13, 2023

BUY
$23.01 - $32.46 $44,110 - $62,225
1,917 Added 5.83%
34,810 $837,000
Q2 2023

Aug 04, 2023

BUY
$29.32 - $35.99 $65,061 - $79,861
2,219 Added 7.23%
32,893 $1.05 Million
Q1 2023

May 12, 2023

BUY
$30.15 - $48.79 $18,391 - $29,761
610 Added 2.03%
30,674 $939,000
Q4 2022

Feb 10, 2023

SELL
$36.73 - $51.6 $4,040 - $5,676
-110 Reduced 0.36%
30,064 $1.18 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $16,950 - $29,952
426 Added 1.43%
30,174 $1.44 Million
Q2 2022

Aug 12, 2022

BUY
$29.86 - $62.36 $129,413 - $270,268
4,334 Added 17.05%
29,748 $1.15 Million
Q1 2022

May 13, 2022

SELL
$53.73 - $82.16 $96,122 - $146,984
-1,789 Reduced 6.58%
25,414 $1.46 Million
Q4 2021

Feb 11, 2022

SELL
$68.02 - $99.06 $5,441 - $7,924
-80 Reduced 0.29%
27,203 $2.17 Million
Q3 2021

Nov 12, 2021

BUY
$84.37 - $133.6 $80,826 - $127,988
958 Added 3.64%
27,283 $2.37 Million
Q2 2021

Aug 13, 2021

BUY
$64.12 - $128.71 $196,912 - $395,268
3,071 Added 13.21%
26,325 $3.39 Million
Q1 2021

May 07, 2021

BUY
$71.28 - $120.75 $4,348 - $7,365
61 Added 0.26%
23,254 $1.86 Million
Q4 2020

Feb 12, 2021

BUY
$22.24 - $95.63 $45,858 - $197,189
2,062 Added 9.76%
23,193 $1.89 Million
Q3 2020

Nov 04, 2020

BUY
$19.0 - $30.57 $258,381 - $415,721
13,599 Added 180.55%
21,131 $520,000
Q2 2020

Aug 12, 2020

BUY
$15.26 - $28.66 $3,982 - $7,480
261 Added 3.59%
7,532 $211,000
Q1 2020

May 04, 2020

BUY
$13.31 - $29.2 $96,777 - $212,313
7,271 New
7,271 $131,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.